34
total announcements
SHILPAMED.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 14 Oct 2026
Market Cap
₹19,042 Cr
P/E (TTM)
68.8
P/E (Forward)
46.7
EPS (TTM)
₹14.16
52W Low
₹259.50
52W High
₹1,095.00
Dividend Yield
0.06%
Beta
0.35
Price / Book
7.4
Debt / Equity
25.5
Revenue (TTM)
₹1,683 Cr
Gross Margin
69.35%
Operating Margin
21.70%
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange regarding the appointment of Dr. Uday N. Harle as Chief Executive Officer (CEO) of Shilpa Biologicals Private Limited, a wholly owned subsidiary, with effect from August 03, 2026.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about the schedule of its Q1FY27 Earnings Conference Call, to be held on August 05, 2026, at 16:00 hrs.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about Credit Rating revision by India Ratings and Research Pvt Ltd (Fitch Group) for its material subsidiary Shilpa Biologicals Private Limited. The revised ratings are IND A+/Stable/IND A1+ for bank loan facilities.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about the resignation of Dr. Sridevi Khambhampaty as Chief Executive Officer (CEO) of Shilpa Biologicals Private Limited, a material subsidiary, due to personal commitments.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about a revision in credit rating issued by India Ratings and Research Pvt. Ltd (Fitch Group) for the company and its subsidiary Shilpa Pharma Lifesciences Ltd. The rating for bank loan facilities has been upgraded to IND AA- from IND A+ with a Stable Outlook.
Shilpa Medicare Limited
Shilpa Medicare Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the details of securities dematerialized or rematerialized during the quarter ended June 30, 2026, as required under Regulation 74(5).
Shilpa Medicare Limited
Shilpa Medicare Limited has announced its audited financial results for the fourth quarter and financial year ended March 31, 2026, along with the appointment of cost auditors and internal auditors, and other corporate updates.
Shilpa Medicare Limited
Shilpa Medicare's wholly owned subsidiary, Shilpa Biologicals, has entered into a co-development and supply agreement with Orion Corporation for intravenous(IV) nivolumab biosimilar. The agreement combines Shilpa's manufacturing capabilities with Orion's commercial and regulatory expertise.
Shilpa Medicare Limited
Shilpa Medicare Limited has published a notice to shareholders regarding the transfer of unclaimed dividends and shares to the Investor Education and Protection Fund (IEPF) as per SEBI Listing Regulations.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange regarding the closure of the trading window for its designated persons and their relatives due to the upcoming declaration of unaudited financial results for the quarter ended 30 June 2026.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about a settlement agreement between its subsidiary, Shilpa Biologicals Pvt. Ltd, and Sartorius Stedim India Pvt. Ltd. for a payment of Rs. 9,00,00,000 to settle a dispute.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about Copy of Newspaper Publication regarding shifting of Registered office.
Shilpa Medicare Limited
Shilpa Medicare Limited, through its material subsidiary Shilpa Biologicals Private Ltd, has commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP Manufacturing Facility. This facility is one of India's few integrated sites for ADC Drug Substance production, designed to meet global regulatory standards. Leveraging Shilpa's 25-year expertise in highly potent compounds, this expansion strategically positions the company as a key Contract Development and Manufacturing Organization (CDMO) partner for global biotech and pharmaceutical companies in the high-value oncology segment.
Shilpa Medicare Limited
Shilpa Medicare Limited has announced the successful conclusion of its postal ballot, with shareholders approving a special resolution to shift the company's registered office from one state to another. This change also necessitates an alteration to the situation clause of the Memorandum of Association. The company has submitted the scrutinizer's report and voting results to the exchanges, confirming the resolution was passed with the requisite majority.